07:00 , Jun 5, 2014 |  BC Innovations  |  Strategy

Sanford-Burnham goes fourth

Sanford-Burnham Medical Research Institute 's outreach to industry has resulted historically in deals focused either on a narrow range of projects or the work of individual investigators, but the institute also has been seeking broader...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

Azor/Sevikar olmesartan/amlodipine regulatory update

FDA issued a drug safety communication warning that hypertension drug olmesartan can cause intestinal problems known as sprue-like enteropathy, which includes symptoms such as severe, chronic diarrhea with substantial weight loss. FDA said it approved...
07:00 , Apr 23, 2012 |  BC Week In Review  |  Company News

Daiichi Sankyo, Ranbaxy sales and marketing update

Ranbaxy's Terapia Ranbaxy Romanian subsidiary launched Sevikar in Romania to manage hypertension. Sevikar is a fixed-dose combination of olmesartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker, and hydrochlorothiazide, a diuretic. Details...
08:00 , Dec 5, 2011 |  BC Week In Review  |  Company News

Daiichi Sankyo sales and marketing update

Daiichi's Daiichi Sankyo UK unit launched Sevikar HCT in the U.K. to manage hypertension. The fixed-dose combination of olmesartan, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker, and hydrochlorothiazide, a diuretic, is...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

Sevikar HCT regulatory update

The Scottish Medicines Consortium recommended the use of Sevikar HCT from Daiichi Sankyo on the National Health Service (NHS) in Scotland as substitution therapy in adult patients whose blood pressure is adequately controlled on the...
07:00 , May 16, 2011 |  BC Week In Review  |  Company News

Daiichi Sankyo, Forest Laboratories cardiovascular news

Forest and Daiichi received subpoenas from the Office of the U.S. Attorney for the District of Massachusetts requesting documents related to hypertension drugs Benicar olmesartan, Benicar HCT and Azor olmesartan/amlodipine. Forest co-promoted the products with...
07:00 , May 16, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) was off $0.04 to $8.36 on Friday after the company resubmitted an NDA to FDA for Iluvien to treat diabetic macular edema. According to Alimera, FDA indicated that the...
00:33 , May 10, 2011 |  BC Extra  |  Company News

Forest receives subpoena on Benicar, Azor

Forest Laboratories Inc. (NYSE:FRX) said late Monday that it received a subpoena from the Office of the U.S. Attorney for the District of Massachusetts requesting documents related to hypertension drugs Benicar olmesartan, Benicar HCT and...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Azor: Preliminary Phase IV data

Preliminary data from the open-label, single-arm, dose-titration, U.S. Phase IV BP CRUSH trial in 999 patients with uncontrolled hypertension on monotherapy and who switched to Azor without a washout period showed that 75.8% of patients...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Olmesartan/amlodipine/hydrochlorothiazide: Phase III data

Data from the double-blind portion of the Phase III TRINITY trial in 2,492 patients with moderate-to-severe hypertension showed that the olmesartan/amlodipine/hydrochlorothiazide triple combination therapy met the primary endpoint of a significantly greater reduction in mean...